The dose escalation design tested different starting doses (2 mg vs 4 mg) to evaluate tolerability
Preliminary findings indicate that TB-500 might enhance not only the viability, angiogenesis, and migration of HUVEC but could also elevate the expression of angiopoietin-2 (Ang2), TEK receptor tyrosine kinase 2 (tie2), vascular endothelial growth factor A (VEGFA), NOTCH1 intracellular domain (N1ICD), Notch receptor 3 (Notch3), NF-B, and phosphorylated (p)-p65 in these cells
Medical and Editorial Review This final article has been reviewed for medical context, scientific accuracy, evidence presentation, patient-safety language and editorial clarity by the multidisciplinary panel below
After reconstitution: Store at 28 C , protect from light, and avoid repeated temperature cycling
Maybe someday
Vasquez-Soltero, and A